MyoTherix is a venture-supported biotech focused on developing novel therapeutics that target both cardiac and skeletal muscle weakness in Duchenne and other muscular dystrophies. Its lead research program aims to improve cardiac and skeletal muscle function, reduce inflammation, and facilitate new muscle regeneration. The company is conducting preclinical studies in mouse models and additional preclinical development work. CureDuchenne Ventures LLC invested $1 million to support these preclinical programs. MyoTherix’s work targets a mechanism intended to benefit patients regardless of their specific mutation. The company is led by co‑founder John Kincaid, who commented on advancing this new approach to treatment.

Total raised

$1M

Funding rounds

1

Latest round

Equity

Latest activity

Sep 2015